Next Article in Journal
Functional Genomics and Immunologic Tools: The Impact of Viral and Host Genetic Variations on the Outcome of Zika Virus Infection
Previous Article in Journal
Influenza Virus Infection of Human Lymphocytes Occurs in the Immune Cell Cluster of the Developing Antiviral Response

Going (Reo)Viral: Factors Promoting Successful Reoviral Oncolytic Infection

Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada
Department of Gastroenterology, Nagoya City West Medical Center, Kita-Ku, Nagoya 467-8601, Japan
Department of Medical Microbiology and Immunology, Li Ka Shing Institute of Virology, University of Alberta, Edmonton, AB T6G 2E1, Canada
Author to whom correspondence should be addressed.
Viruses 2018, 10(8), 421;
Received: 30 June 2018 / Revised: 9 August 2018 / Accepted: 9 August 2018 / Published: 11 August 2018
(This article belongs to the Section Animal Viruses)
Oncolytic viruses show intriguing potential as cancer therapeutic agents. These viruses are capable of selectively targeting and killing cancerous cells while leaving healthy cells largely unaffected. The use of oncolytic viruses for cancer treatments in selected circumstances has recently been approved by the Food and Drug Administration (FDA) of the US and work is progressing on engineering viral vectors for enhanced selectivity, efficacy and safety. However, a better fundamental understanding of tumour and viral biology is essential for the continued advancement of the oncolytic field. This knowledge will not only help to engineer more potent and effective viruses but may also contribute to the identification of biomarkers that can determine which patients will benefit most from this treatment. A mechanistic understanding of the overlapping activity of viral and standard chemotherapeutics will enable the development of better combinational approaches to improve patient outcomes. In this review, we will examine each of the factors that contribute to productive viral infections in cancerous cells versus healthy cells. Special attention will be paid to reovirus as it is a well-studied virus and the only wild-type virus to have received orphan drug designation by the FDA. Although considerable insight into reoviral biology exists, there remain numerous deficiencies in our understanding of the factors regulating its successful oncolytic infection. Here we will discuss what is known to regulate infection as well as speculate about potential new mechanisms that may enhance successful replication. A joint appreciation of both tumour and viral biology will drive innovation for the next generation of reoviral mediated oncolytic therapy. View Full-Text
Keywords: oncolytic virus; reovirus; oncolysis; susceptibility oncolytic virus; reovirus; oncolysis; susceptibility
Show Figures

Figure 1

MDPI and ACS Style

Bourhill, T.; Mori, Y.; Rancourt, D.E.; Shmulevitz, M.; Johnston, R.N. Going (Reo)Viral: Factors Promoting Successful Reoviral Oncolytic Infection. Viruses 2018, 10, 421.

AMA Style

Bourhill T, Mori Y, Rancourt DE, Shmulevitz M, Johnston RN. Going (Reo)Viral: Factors Promoting Successful Reoviral Oncolytic Infection. Viruses. 2018; 10(8):421.

Chicago/Turabian Style

Bourhill, Tarryn, Yoshinori Mori, Derrick E. Rancourt, Maya Shmulevitz, and Randal N. Johnston. 2018. "Going (Reo)Viral: Factors Promoting Successful Reoviral Oncolytic Infection" Viruses 10, no. 8: 421.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop